J0202 HCPCS code: Injection, alemtuzumab, 1 mg
J0202 is the HCPCS Level II code for injection, alemtuzumab, 1 mg. In 2024 Medicare paid an average of $1,161.77 per service for J0202 across 740 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 12 per day on outpatient hospital claims. Medicare volume fell 49% from 2022 to 2024 (1,446 to 740 services). In 2024, about 21 clinicians billed Medicare for J0202 for 16 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2016-01-01 |
| Last action effective | 2016-01-01 |
Who bills J0202 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 21 |
| Medicare beneficiaries | 16 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0202, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 1,446 | 37 | $1,484.26 | $1,185.07 |
| 2023 | 1,336 | 28 | $1,439.53 | $1,146.96 |
| 2024 | 740 | 16 | $1,458.14 | $1,161.77 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 12 | Prescribing Information |
| practitioner claims | 12 | Prescribing Information |
Medicare policy articles for this code
- A55310: Billing and Coding: Instructions for Lemtrada® (alemtuzumab) When Used in the Treatment of Relapsing Multiple Sclerosis (Palmetto GBA (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| G35.A | Relapsing-remitting multiple sclerosis | 1 |
| G35.C1 | Active secondary progressive multiple sclerosis | 1 |
What changed for J0202
- 2016-01-01: J0202 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0202?
J0202 is the HCPCS Level II code for injection, alemtuzumab, 1 mg. Short descriptor: "Injection, alemtuzumab".
How much does Medicare pay for J0202?
In 2024, the average Medicare payment was $1,161.77 per service (average allowed $1,458.14).
Does Medicare cover J0202?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J0202?
Medicare policy articles that cite J0202 list 2 covered ICD-10-CM diagnosis codes across 1 article. The most cited include G35.A (Relapsing-remitting multiple sclerosis), G35.C1 (Active secondary progressive multiple sclerosis). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J0202 can be billed per day?
12 on outpatient hospital claims; 12 on practitioner claims (NCCI medically unlikely edits).
Related J02 codes
- J0200 — Injection, alatrofloxacin mesylate, 100 mg
- J0205 — Injection, alglucerase, per 10 units
- J0206 — Injection, allopurinol sodium, 1 mg
- J0207 — Injection, amifostine, 500 mg
- J0208 — Injection, sodium thiosulfate (pedmark), 100 mg
- J0209 — Injection, sodium thiosulfate (hope), 100 mg
- J0210 — Injection, methyldopate hcl, up to 250 mg
- J0211 — Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg (nithiodote)
- J0215 — Injection, alefacept, 0.5 mg
- J0216 — Injection, alfentanil hydrochloride, 500 micrograms
- J0217 — Injection, velmanase alfa-tycv, 1 mg
- J0218 — Injection, olipudase alfa-rpcp, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0202
- Watch J0202 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0202
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.